
Starting a GLP-1 medication changes more than the number on the scale. Appetite shifts, daily routines shift, and for some people the way they feel from one week to the next shifts too. It is no surprise that GLP-1 mood changes have become one of the most common questions people bring to a consultation. Will this medication make me anxious? Could it make depression worse? Why do I feel flat, weepy, or irritable this week?
The honest answer has several parts. Regulators and large randomized trials have not found that these medications raise the risk of depression or suicidal thoughts in people without major psychiatric illness. At the same time, those studies leave real gaps, and mood can change during treatment for reasons that have little to do with the medication itself. This guide covers what the research shows, what it cannot tell us, the other factors that move mood during weight loss, and how to raise the subject with your provider.
This article is general education, not medical advice or a diagnosis. If you are in crisis or thinking about harming yourself, skip ahead to the section on getting help right away.
Why People Ask About GLP-1 Mood Changes
There are a few reasons this topic gets so much attention. GLP-1 medications act on hormone signaling involved in appetite and digestion, and the same signaling pathways are present in parts of the brain. That makes it reasonable to ask whether feelings, not just hunger, might shift. Early safety reports and news coverage from 2023 onward raised the question publicly, and regulators in several countries took a closer look.
There is also a more everyday explanation. Losing weight is a big life change. Food is tied to comfort, celebration, routine, and stress relief for many of us, and when appetite quiets down, the coping habits built around eating can feel suddenly exposed. If you have read about how these medications can quiet constant thoughts about food in our article on semaglutide and food noise, it is easy to see why some people wonder about other mental effects too.
The useful way to approach the question is to separate three things: what the medication itself appears to do, what the underlying health condition does, and what the experience of changing your body and habits does. Each can influence mood, and they often overlap.
What Regulators Have Concluded About Mood and Suicidal Thoughts
The most direct evidence comes from regulators who reviewed the safety data in detail.
In April 2024, the European Medicines Agency’s safety committee finished a review that began after case reports of suicidal thoughts and self-injury in people using liraglutide and semaglutide. The committee concluded that the available evidence did not support a causal link between this class of medications and suicidal or self-injurious thoughts and actions, and it decided that no change to the product information was needed. The committee also said the manufacturers would continue to monitor new evidence.
In January 2026, the U.S. Food and Drug Administration reached a similar conclusion. After a comprehensive review, the agency asked the makers of brand-name GLP-1 weight-loss medications to remove the suicidal behavior and ideation warning from their labels, saying the review found no increased risk. News coverage of the announcement reported that the analysis covered 91 clinical trials with 107,910 participants, of whom 60,338 received a GLP-1 medication and 47,572 received placebo. The FDA also explained that the warning language had originally been carried over from older weight-loss medicines, not written because of a specific signal with this class.
One point of context matters here. Those labels and trials concern brand-name products. Medica Weight Loss offers compounded semaglutide and tirzepatide prepared by a state-licensed compounding pharmacy on a valid individual prescription, and compounded medications are not evaluated by the FDA the way brand-name products are. Research on brand-name medications tells us about the active ingredients and how people respond to them in studies, but it is not a review of any particular compounded preparation. Your provider can explain how that distinction applies to you during a consultation. If you would like background on how compounding works, our guide to what a compounding pharmacy is covers it.
What the Clinical Trials Show About Depression and Anxiety
Regulatory conclusions rest on the underlying studies, so it helps to look at those directly. Researchers have analyzed mood outcomes from the large weight-management trials, mostly using two standard tools. The Patient Health Questionnaire-9, or PHQ-9, is a nine-question screening survey for depressive symptoms. The Columbia-Suicide Severity Rating Scale is a structured questionnaire that asks about suicidal thoughts and behavior.
Semaglutide. A pooled post hoc analysis of the STEP 1, 2, 3, and 5 trials, published in JAMA Internal Medicine in 2024, included 3,377 participants from STEP 1, 2, and 3 and another 304 from STEP 5. People who took the 2.4 mg weekly dose were no more likely to develop symptoms of depression or suicidal thoughts than people who took placebo. Average PHQ-9 scores at week 68 were 2.0 with semaglutide and 2.4 with placebo, both in the range considered minimal or no depressive symptoms, and the semaglutide group was less likely to move into a more severe depression category (odds ratio 0.63). One percent or fewer of participants reported suicidal thoughts or behavior, with no difference between groups. The trials were funded by the manufacturer, which is worth knowing when you weigh the results.
Tirzepatide. A pooled analysis of the SURMOUNT-1, 2, and 3 trials, published in Obesity in January 2026, covered 4,056 adults (2,806 on tirzepatide and 1,250 on placebo) followed for 72 weeks. Average PHQ-9 scores improved slightly more with tirzepatide (a change of -0.7 versus -0.1 with placebo), though the authors described the difference as too small to be clinically meaningful. Suicidal ideation was reported by 0.6% of participants in each group. Depressive disorder adverse events were reported by 1.5% of the tirzepatide group versus 2.1% of the placebo group, and anxiety symptoms by 1.5% versus 3.5%. The analysis also noted two cases of nonfatal suicidal behavior in the tirzepatide group and none in the placebo group, and the authors said the numbers were too small to tell whether that reflected the treatment, the participants, or chance. This analysis was funded by the manufacturer too. For background on the main efficacy trial, see SURMOUNT-1 in the New England Journal of Medicine.
The class as a whole. A 2025 systematic review and meta-analysis of randomized, placebo-controlled trials in JAMA Psychiatry looked at psychiatric, cognitive, and quality-of-life outcomes across more than 100,000 participants. As summarized by HealthDay, GLP-1 treatment was not associated with a higher risk of psychiatric adverse events or worsening depressive symptoms, and it was associated with improvements in restrained eating, emotional eating, and quality of life.
Taken together, the trial evidence is reassuring for adults who do not have major psychiatric illness. It is not a promise about any one person, and the next sections explain the limits.
What Real-World Studies Add, and Why They Are Harder to Read
Trials are tightly controlled, so researchers also study large health-record databases to see what happens in everyday practice. These studies are valuable, but they cannot fully separate the effect of a medication from differences between the people who receive it.
An analysis of electronic health records led by researchers at Case Western Reserve University and the National Institute on Drug Abuse, published in Nature Medicine, examined more than 240,000 people with overweight or obesity. Those prescribed semaglutide had a lower risk of first-time and recurring suicidal ideation than people prescribed other weight-loss medications, with reductions in the range of 49% to 73% depending on the group, according to the NIH summary of the study.
A Swedish and Danish registry study in JAMA Internal Medicine followed 124,517 new users of GLP-1 medications and 174,036 new users of a different diabetes drug class for about 2.5 years. It found no increase in depression and anxiety-related disorders (hazard ratio 1.01) and a lower rate of suicide death and nonfatal self-harm (hazard ratio 0.83). Most participants had type 2 diabetes, and the authors noted that some suicide deaths may be misclassified and that longer-term risks could not be ruled out.
Those findings point in a reassuring direction, but the physicians who wrote the accompanying editorial were careful. They said neither study clearly answers whether these medications worsen symptoms in people who already have conditions such as moderate or severe depression, and they concluded that continued monitoring of mental health is essential. That is a fair summary of where the field stands: no signal of harm in the broad population, and an honest acknowledgment that some groups were underrepresented.
Why Anxiety and Depression Were Common Before Treatment Started
Mood symptoms are not rare in people seeking weight-loss treatment, and that is part of why it is hard to pin a new feeling on a new medication. A well-known meta-analysis in Archives of General Psychiatry pooled 15 longitudinal studies and confirmed a two-way relationship between obesity and depression. People with obesity had a 55% higher risk of developing depression over time, and people with depression had a 58% higher risk of becoming obese.
The reasons are layered. Living with weight stigma, chronic pain, poor sleep, and the stress of repeated unsuccessful diets can all weigh on mood. Biology contributes too, through inflammation, hormones, and the way stress affects appetite. Our articles on the science of obesity and on how stress affects weight loss explore that biology in more detail.
The practical takeaway is that a baseline matters. If you already feel anxious or low before your first dose, a hard week during treatment is difficult to interpret on its own. That is why a good starting conversation includes your mental health history, not just your weight and lab work.
Other Reasons Your Mood Can Shift During Treatment
Even when the medication is not the cause, mood can genuinely change while you are on a GLP-1 program. These are the most common non-drug contributors worth considering.
- Losing food as a coping tool. If you have relied on snacks or comfort meals to manage stress, boredom, or loneliness, reduced appetite can leave those feelings with nowhere to go. That can show up as restlessness, irritability, or a low mood. We cover this in depth in our guide to emotional eating and weight loss medication, including ways to build other coping skills.
- Eating too little. Very low intake can bring fatigue, trouble concentrating, shakiness, and a short temper, all of which feel a lot like anxiety or low mood. If appetite is very small, read our article on eating too little on GLP-1 medication and tell your provider.
- Disrupted sleep. Nausea, nighttime discomfort, or early-morning waking can cut into rest, and poor sleep is one of the strongest everyday drivers of mood and worry. See our piece on sleep and weight loss for practical steps.
- Physical side effects. Nausea, constipation, headaches, and fatigue are common early on, and feeling physically unwell tends to lower patience and mood. Our guides to semaglutide side effects and tirzepatide side effects explain what is typical and what to report.
- Dose changes. Many people notice that physical and emotional shifts cluster around the days after a dose is raised. How and why providers adjust doses is covered in our article on GLP-1 dose adjustment.
- Frustration with the pace. Weight loss rarely moves in a straight line, and plateaus can be discouraging. Our guide to the weight loss plateau explains what is normal.
- Identity and body image changes. A changing body can bring unexpected feelings, including grief for old routines, anxiety about attention, or a sense that a familiar self is shifting. Even practical details like buying clothes while losing weight can stir this up.
- Changes in alcohol habits. Some people drink less on treatment, which can affect sleep and social routines. We discuss the research in semaglutide and alcohol cravings.
- Everything else in your life. Work stress, family strain, grief, seasonal changes, and hormonal transitions such as perimenopause all affect mood, and they do not pause because a new medication started.
Naming these factors is not a way of dismissing how you feel. It is a way of giving your provider more to work with, because the right response to poor sleep, under-eating, or a rough dose adjustment is very different from the right response to persistent depression.
Mood Changes Worth Paying Attention To
Everyone has off days. What matters is the pattern. Consider reaching out to your provider if you notice any of the following, especially if it lasts longer than a couple of weeks or interferes with daily life:
- A persistently low, empty, or hopeless mood
- Losing interest in things you normally enjoy
- New or worsening anxiety, constant worry, or panic attacks
- Unusual irritability or anger that feels out of character
- Major changes in sleep, energy, or concentration that food and rest do not fix
- Withdrawing from friends and family
- Feeling that you are a burden, or that things will not get better
These are general signs, not a checklist for diagnosing yourself. The National Institute of Mental Health has plain-language overviews of depression and anxiety disorders if you want to learn more about what they involve and how they are treated. Both are common and treatable.
If You Already Live With Anxiety or Depression
Many people who are considering a GLP-1 program already manage anxiety, depression, or both. That does not automatically rule out treatment, but it does call for a more careful conversation, for a few reasons.
First, the large trials described above generally excluded people with recent or unstable major depression, other severe psychiatric illness, or a history of suicide attempts. The authors of the tirzepatide analysis said plainly that their results cannot establish psychiatric safety for people with major psychopathology. In other words, the people who may most want reassurance are the people the data speak to least.
Second, your mental health treatment is part of your care team’s picture. If you take medication for anxiety or depression, or see a therapist, tell your provider, and consider letting your mental health clinician know you are starting a weight-loss program. Do not change or stop a psychiatric medication on your own, and do not assume the two do not interact with appetite, weight, or sleep. Coordinating early prevents surprises.
Third, being honest about your history helps you and your provider decide on timing, follow-up frequency, and what to watch for. Our overview of who is a good candidate for medical weight loss describes the kinds of questions a consultation covers.
How to Track Your Mood and Talk to Your Provider
Mood is easy to forget or exaggerate when you are looking back over weeks, so a little tracking goes a long way. You do not need an app. A few lines in a notes file once a day is enough.
- Rate your mood and anxiety. A simple 1 to 10 for each, plus a word or two about why.
- Note sleep and food. Roughly how many hours you slept and whether you ate regular meals.
- Mark injection and dose-change days. This helps you and your provider see whether feelings cluster after a dose.
- Record side effects. Nausea, headaches, and fatigue can look like mood problems.
- Write down life events. A stressful week at work explains a lot.
When you bring this to an appointment, specific details are more useful than general worry. You might ask:
- Given my history, how often should we check in about mood?
- Could my dose, my eating, or my sleep be contributing to how I feel?
- Should we hold at my current dose for longer before making a change?
- Would it help to involve my primary care provider or a mental health professional?
- What symptoms should prompt me to contact you right away?
Raising these questions early is part of a consultation-first approach, and a provider who knows your baseline can respond sooner if something changes.
Everyday Habits That Support Mood During Treatment
None of these replace professional care, but they can make the whole experience steadier.
Eat regularly, even when you are not very hungry. Small, steady meals with protein and fiber help keep energy and focus from crashing. Our 7-day GLP-1 meal plan shows what that can look like.
Protect your sleep. A consistent bedtime, a dark room, and winding down away from screens give mood a better foundation.
Move in ways you enjoy. Walking, gentle strength work, or time outdoors can support mood and energy. It does not need to be intense to be worth doing.
Replace the old coping habit with a new one. If food used to be your wind-down at 9 p.m., decide ahead of time what will take its place, such as a shower, a call with a friend, or a short walk.
Stay connected. Isolation tends to make low mood and anxiety louder. Tell someone you trust that you are starting a program and that you may have ups and downs.
Consider talking with a therapist. Therapy can help with body image, old patterns around food, and the emotional side of change, whether or not you have a diagnosis. For some people, it is the most valuable part of the whole process.
When to Get Help Right Away
If you are having thoughts of suicide or self-harm, or you feel you might act on them, get help immediately. In the United States, you can call or text 988 to reach the 988 Suicide & Crisis Lifeline, which offers free, confidential support at any hour. If you or someone else is in immediate danger, call 911 or go to the nearest emergency room. The SAMHSA helplines page lists additional resources.
Reaching out for help in a crisis comes first. After you are safe, let your prescribing provider know what happened so your care team can adjust the plan. Please do not stop or change any medication on your own, including psychiatric medication, without talking to a clinician. If you are wondering what stopping would involve, our article on what happens if you stop taking semaglutide or tirzepatide explains why the decision is best made with your provider.
Frequently Asked Questions About GLP-1 Mood Changes
Do GLP-1 medications cause depression?
In the large trial analyses and regulatory reviews described above, GLP-1 medications were not found to increase the risk of depression in adults without major psychiatric illness. Those studies had limits, including exclusion of people with severe or unstable psychiatric conditions, so it is still important to report any new or worsening symptoms to your provider.
Can GLP-1 medications cause anxiety?
Anxiety is not listed as a clear risk in the trial data discussed here. In the pooled tirzepatide analysis, anxiety symptoms were actually reported somewhat less often than on placebo. Still, under-eating, poor sleep, and physical side effects can feel like anxiety, so it helps to look at the whole picture with your provider.
Why do I feel emotionally flat or different on treatment?
There is no single explanation. Reduced appetite can change how you experience food-related pleasure and comfort, and sleep, nutrition, and dose changes can all play a part. Research on this specific experience is still limited, so it is worth describing the feeling to your provider rather than guessing.
Should I avoid a GLP-1 program if I have a history of depression or anxiety?
Not necessarily, but it is a conversation to have before starting. Your provider can consider your history, your current treatment, and how closely to follow up. If you are working with a mental health clinician, keeping them informed is a good idea.
Will my mood go back to normal if I stop the medication?
That depends on what was driving the change, and it is a decision to make with your provider rather than on your own. Mood shifts caused by sleep, food intake, or life stress may need their own solutions regardless of the medication.
When should I contact my provider about mood?
Contact them if low mood, worry, or irritability lasts more than a couple of weeks, interferes with daily life, or feels out of character. Contact emergency services or the 988 Lifeline right away for thoughts of self-harm.
The Bottom Line on GLP-1 Mood Changes
The weight of current evidence from regulators, randomized trials, and large real-world studies is that GLP-1 medications do not appear to increase depression or suicidal thoughts in adults without major psychiatric illness. The evidence is thinner for people with significant psychiatric histories, and mood can legitimately shift during treatment for reasons ranging from lost coping habits to poor sleep to the plain emotional weight of changing your body.
What helps most is paying attention, writing down patterns, and telling your care team early. If you are curious whether a provider-guided program makes sense for you, you can start with our step-by-step guide or learn how the online process, costs, and expectations work. A consultation is the place to bring your history, your questions, and your concerns, and nothing in it is a commitment.
Medica Weight Loss offers compounded semaglutide and tirzepatide, prepared by a state-licensed compounding pharmacy based on a valid individual prescription. These compounded medications are not FDA-approved — they have not been evaluated by the FDA for safety, effectiveness, or quality. Any reference to FDA-approved medications elsewhere refers solely to brand-name formulations such as Wegovy®, Ozempic®, Zepbound®, and Mounjaro®, which are not what Medica Weight Loss dispenses.